In addition to regulating HIF-2α, the VHL E3 ubiquitin ligase has other substrates that may also play important roles in the progression of ccRCC because ccRCC patient samples exhibited differential sensitivity to HIF-2α inhibitors (29, 30, 31). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.